Day: March 9, 2026

Strong full year gross profit growth and over 260 basis points of gross margin expansion despite challenging industry environment Operating cash flow of $35 million and Adjusted Free Cash Flow of $31 million, up 45% year over year Projecting growth in 2026 CHICAGO, March 09, 2026 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a diversified manufacturer and supplier of railroad freight cars, railcar parts and components, today reported results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 HighlightsRevenues of $125.6 million, compared to $137.7 million in the fourth quarter of 2024, with railcar deliveries of 1,172 units compared to 1,019 units in the prior year period Gross margin of 13.4% with gross profit of $16.8 million, compared to...

Dallas, Texas, March 09, 2026 (GLOBE NEWSWIRE) — Kronos Worldwide, Inc. (NYSE:KRO) today reported a net loss of $82.8 million, or $.72 per share, in the fourth quarter of 2025 compared to a net loss of $13.2 million, or $.12 per share, in the fourth quarter of 2024. For the full year of 2025, Kronos Worldwide reported a net loss of $110.9 million, or $.96 per share, compared to net income of $86.2 million, or $.75 per share, for the full year of 2024. Our net loss increased in the fourth quarter of 2025 compared to the fourth quarter of 2024 due to lower income from operations primarily due to higher unabsorbed fixed production costs resulting from production curtailments and lower average TiO2 selling prices somewhat offset by higher sales volumes. In addition, we recorded non-cash deferred income tax expense of $8.5 million ($.07...

Improves Q4 Combined Ratio to 92.1%, Achieves Record Full-Year Underwriting Income. GRAND CAYMAN, Cayman Islands, March 09, 2026 (GLOBE NEWSWIRE) — Greenlight Capital Re, Ltd. (NASDAQ: GLRE) (“Greenlight Re” or the “Company”) today reported its financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 Highlights (all comparisons are to fourth quarter 2024 unless noted otherwise):Gross premiums written increased 12% to $161.3 million; Net premiums earned increased 12% to $165.6 million; Net underwriting income of $13.0 million, compared to an underwriting loss of $18.0 million; Combined ratio of 92.1%, compared to 112.1%; Total investment income of $44.8 million, compared to $2.6 million; Net income of $49.3 million, or $1.44 per diluted ordinary share, compared to a net loss of $27.4 million,...

Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million. Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million. Successfully launched oral Wegovy subsequent to year end, with over 80% of new weight management patients initiating branded therapy and Q1 sign-ups at record levels. Exited 2025 with $36.8 million of cash and no debt, positioning LifeMD for accelerated investments in growth. Benefits infrastructure on track to cover approximately 220 million Americans in second quarter; women’s health offering seeing strong early patient growth.Conference call begins at 4:30 p.m. Eastern time today NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results...

Net Asset Value of $8.09 Per Share as of December 31, 2025 Recent 2026 Portfolio Company Financings Expected to Add an Estimated $5.00 – $6.50 to Net Asset Value Per Share NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) — SuRo Capital Corp. (“SuRo Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: SSSS) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. Net assets totaled approximately $205.3 million, or $8.09 per share, at December 31, 2025, as compared to $9.23 per share, at September 30, 2025 and $6.68 per share at December 31, 2024. “2025 was a year of strong performance across our portfolio, underscoring the continued execution and value creation at several of our largest investments. That momentum has continued into 2026, with a number of our portfolio companies having...

HOUSTON, March 09, 2026 (GLOBE NEWSWIRE) — Amplify Energy Corp. (NYSE: AMPY) (“Amplify,” the “Company,” “us,” or “our”) announced today updates to its strategic initiatives, year-end 2025 proved reserves, operating and financial results for the fourth quarter and full-year 2025, and full-year 2026 development plans and guidance for the Company. Strategic Initiatives Update In the third quarter of 2025, Amplify communicated its strategic plan with three core tenets: (1) simplify the portfolio, (2) strengthen the balance sheet, and (3) focus resources on our assets with the highest potential upside opportunities. In 2025, the Company made significant progress on all three fronts. Key highlights include:Completed six separate transactions for total consideration of approximately $250 million (excluding certain post-closing adjustments)In...

SHAKOPEE, Minn., March 09, 2026 (GLOBE NEWSWIRE) — Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (Nasdaq: CPHC) today reported financial results for the fourth quarter and full year ended December 31, 2025.($ in thousands, except per share data and percentages)         Three Months Ended December 31,   Twelve Months Ended December 31,  2025   2024   Change   2025   2024   ChangeNet revenues  $12,446   $11,978   3.9%   $59,568   $61,562   (3.2%)                       Net income (loss) (1) ($390)   ($1,245)   (68.7%)   ($529)   $2,113   (125.1%)                       Adjusted EBITDA (2) $2,288   $1,497   52.8%   $9,410   $10,805   (12.9%)                       Basic EPS ($0.08)   ($0.25)   (68.0%)   ($0.10)   $0.42   (123.8%)Diluted EPS ($0.08)   ($0.25)   (68.0%)   ($0.10)   $0.42   (123.8%) (1)   Net...

Q4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter FY 2025 net revenue of $106.5 million, driven by growth in MIPLYFFA® net revenue to $87.4 million 2025 EPS of $1.40 basic and $1.35 diluted  Company to host conference call and webcast TODAY, March 9, 2026, at 4:30 p.m. ET BOSTON, March 09, 2026 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the fourth quarter and full year ended December 31, 2025. “MIPLYFFA is making a meaningful difference for patients with Niemann-Pick disease type C, and its strong, accelerating performance reinforces our confidence in its long-term potential,” said Neil F. McFarlane, Zevra’s President...

Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026  Advancing SEP-479 (PTH1R Agonist) Toward Phase 1 Initiation in First Half of 2026 Cash Runway Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) — Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted pipeline progress and anticipated milestones and reported financial results for the fourth quarter and full year ended December 31, 2025.   “We made significant strides advancing our pipeline in the past year, and 2026 has already delivered a meaningful milestone with positive Phase...

– Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment – – Multiple meaningful milestones targeted in the coming months, including completion of patient recruitment in the U.S. pivotal ReSTART skin cancer trial, in the U.S. pilot IMPACT pancreatic cancer trial, and in the U.S. recurrent glioblastoma multiforme feasibility trial – – $76.9 million in cash, cash equivalents & deposits provides continued balance sheet strength for clinical advancement and commercial preparation – JERUSALEM, March 09, 2026 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the...